FORM 4				OMB APPROVAL			
Check this box if no longer subject to Sec Form 4 or Form 5 obligations may contin Instruction 1(b). Check this box to indicate that a transacti made pursuant to a contract, instruction o plan for the purchase or sale of equity sec the issuer that is intended to satisfy the af defense conditions of Rule 10b5-1(c). Sec Instruction 10. (Print or Type Responses)	ue. <i>See</i> on was r written urities of Filed pursuan firmative	UNITED STATES SECURITIES AND EXCHANGE CO Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHI It to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h)	P OF SECURITIES	d average burden hours per			
1. Name and Address of Reporting Person * Elstein Amir		2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [TEVA]	5. Relationship of Reporting Person(s) to Is (Check all app	olicable)			
(Last) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/05/2025	X Director Officer (give title below)	10% Owner Other (specify below)			
(Street) Tel Aviv, L3 6944020		4. If Amendment, Date Original Filed (Month/Day/Year)	X Form filed by One Reporting Person	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	7					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	Date (Month	Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form:	Beneficial
		(Month/Day /Year)	Code	V	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Ordinary Shares (1)	06/06/2025		M		9,632	A	(2)	2,103,963	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transact Code (Instr. 8)		Derivative Securities		Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	of Derivative Securities Beneficially		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following	Direct (D) or Indirect (I) (Instr. 4)	
Restricted Share Units	(2)	06/06/2025		М			9,632	(3)	(3)	Ordinary Shares ⁽¹⁾	9,632	\$ 0	0	D	
Restricted Share Units	(2)	06/05/2025		A		14,492		(4)	(4)	Ordinary Shares ⁽¹⁾	14,492	\$ 0	14,492	D	

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- 3. Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
- 4. Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.